Evidence map›Paper›PMID 37500340›Full record

ArticleEuropean urology2023

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.

Elizabeth R Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières and 11 more

Erratum issued Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07686744 (A Phase I Clinical Trial of Personalized Neoantigen Peptide Vaccine in Combination With Pembrolizumab for the Safety and Efficacy in Patients With Advanced, Recurrent or Refractory Renal Cell Carcinoma), which is not on this map. Cited by 97 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 5 pooled it
31.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07686744 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase I Clinical Trial of Personalized Neoantigen Peptide Vaccine in Combination With Pembrolizumab for the Safety and Efficacy in Patients With Advanced, Recurrent or Refractory Renal Cell Carcinoma

TypeinterventionalSponsorJian LinRan2026 to 2029Enrolled8ConditionsRenal Cell Carcinoma, Advanced, Recurrent, RefractoryArmsPersonalized Neoantigen Polyepitope Peptide Vaccine
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 5 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2024
    Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 19 institutions in 11 countries.

Elizabeth R PlimackFox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Elizabeth.Plimack@fccc.edu.
Thomas PowlesBarts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, London, UK; Queen Mary University of London, London, UK.
Viktor StusDnipro State Medical University, Dnipro, Dnipropetrovsk Oblast, Ukraine.
Rustem GafanovRussian Scientific Center of Roentgenology and Radiology, Moscow, Russia.
Dmitry NosovCentral Clinical Hospital With Outpatient Clinic, Moscow, Russia.
Tom WaddellThe Christie NHS Foundation Trust, Manchester, UK.
Boris AlekseevP. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russia.
Frédéric PouliotCHU of Québec and Laval University, Québec, QC, Canada.
Bohuslav MelicharPalacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
Denis SoulièresCentre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
Delphine BorchielliniCentre Antoine Lacassagne, Université Côte d'Azur, Nice, France.
Raymond S McDermottAdelaide and Meath Hospital, University College Dublin, Belfield, Dublin, Ireland.
Ihor VynnychenkoSumy Regional Oncology Center, Sumy State University, Sumy, Sumy Oblast, Ukraine.
Yen-Hwa ChangTaipei Veterans General Hospital, Taipei, Taiwan.
Satoshi TamadaBell Land General Hospital, Osaka, Japan.
Michael B AtkinsGeorgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Chenxiang LiMerck & Co., Inc., Rahway, NJ, USA.
Rodolfo PeriniMerck & Co., Inc., Rahway, NJ, USA.
L Rhoda MolifeMSD UK, London, UK.
Jens BedkeUniversity Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
Brian I RiniVanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USBerurando General Hospital · JPCentral Clinical Hospital and Polyclinic · RUCentre Hospitalier de l’Université de Montréal · CADnipro State Medical University · UAFederal State Budgetary Institution Russian Scientific Center of Roentgenoradiology · RUFox Chase Cancer Center · USGeorgetown Lombardi Comprehensive Cancer CenterMinistry of Health of the Russian Federation · RUMSD (UK) Limited (United Kingdom) · GBPalacký University Olomouc · CZQueen Mary University of London · GBSumy State University · UATaipei Veterans General Hospital · TWThe Christie NHS Foundation Trust · GBUniversité Côte d'Azur · FRUniversité Laval · CAUniversity College Dublin · IEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous analyses of KEYNOTE-426, an open-label, phase 3 randomized study, showed superior efficacy of first-line pembrolizumab plus axitinib to sunitinib in advanced clear cell renal cell carcinoma (ccRCC). We report results of the final protocol-prespecified analysis of KEYNOTE-426. Patients received pembrolizumab 200 mg intravenously every 3 wk plus axitinib 5 mg orally twice daily or sunitinib 50 mg orally once daily (4 wk per 6-wk cycle). The dual primary endpoints were overall survival (OS) and progression-free survival (PFS) as per RECIST v1.1 by a blinded independent central review. The secondary endpoints included objective response rate (ORR) and duration of response (DOR). The median study follow-up was 43 (range, 36-51) mo. Benefit with pembrolizumab plus axitinib versus sunitinib was maintained for OS (hazard ratio [HR], 0.73 [95% confidence interval {CI}, 0.60-0.88]), PFS (HR, 0.68 [95% CI, 0.58-0.80]), and ORR (60% vs 40%). The median DOR was 24 (range, 1.4+ to 43+) versus 15 (range, 2.3-43+) mo in the pembrolizumab plus axitinib versus the sunitinib arm. No new safety signals emerged. These results support pembrolizumab plus axitinib as a standard of care for patients with previously untreated advanced ccRCC. PATIENT SUMMARY: Extended results of KEYNOTE-426 support pembrolizumab plus axitinib as the standard of care for advanced clear cell renal cell carcinoma.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsAxitinibFollow-Up StudiesHumansSunitinibAntibodies, Monoclonal, HumanizedAxitinibpembrolizumabSunitinibAxitinibImmunotherapyPembrolizumabRenal cell carcinomaSunitinib

Identifiers

PMID37500340
OpenAlexW4385256763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.